Prostaglandin E2 EP receptors in cardiovascular disease: An update

被引:25
作者
Bryson, Timothy D. [1 ,2 ]
Harding, Pamela [3 ,4 ]
机构
[1] Univ Michigan, Dept Emergency Med, Med Sch, Ann Arbor, MI USA
[2] Univ Michigan, Frankel Cardiovasc Ctr, Med Sch, Ann Arbor, MI USA
[3] Henry Ford Hlth Syst, Hypertens & Vasc Res Div, Dept Internal Med, Detroit, MI 48202 USA
[4] Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA
关键词
Prostaglandin E2; Heart; Ischemia; Arrhythmia; Blood pressure; ISCHEMIA-REPERFUSION INJURY; ANGIOTENSIN-II; BLOOD-PRESSURE; MYOCARDIAL-ISCHEMIA; MICE LACKING; MATRIX METALLOPROTEINASES; CAROTID ATHEROSCLEROSIS; CARDIAC-HYPERTROPHY; SIGNALING PATHWAYS; GENE-EXPRESSION;
D O I
10.1016/j.bcp.2021.114858
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This review article provides an update for the role of prostaglandin E2 receptors (EP1, EP2, EP3 and EP4) in cardiovascular disease. Where possible we have reported citations from the last decade although this was not possible for all of the topics covered due to the paucity of publications. The authors have attempted to cover the subjects of ischemia-reperfusion injury, arrhythmias, hypertension, novel protein binding partners of the EP receptors and their pathophysiological significance, and cardiac regeneration. These latter two topics bring studies of the EP receptors into new and exciting areas of research that are just beginning to be explored. Where there is peer-reviewed literature, the authors have placed particular emphasis on clinical studies although these are limited in number.
引用
收藏
页数:11
相关论文
共 136 条
[1]   Matrix metalloproteinases/tissue inhibitors of metalloproteinases - Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease [J].
Ahmed, SH ;
Clark, LL ;
Pennington, WR ;
Webb, CS ;
Bonnema, DD ;
Leonardi, AH ;
McClure, CD ;
Spinale, FG ;
Zile, MR .
CIRCULATION, 2006, 113 (17) :2089-2096
[2]   IL-1β reduces cardiac lymphatic muscle contraction via COX-2 and PGE2 induction: Potential role in myocarditis [J].
Al-Kofahi, Mahmoud ;
Omura, Seiichi ;
Tsunoda, Ikuo ;
Sato, Fumitaka ;
Becker, Felix ;
Gavins, Felicity N. E. ;
Woolard, Matthew D. ;
Pattillo, Christopher ;
Zawieja, David ;
Muthuchamy, Mariappan ;
Gashev, Anatoliy ;
Shihab, Israa ;
Ghoweba, Mohamed ;
Von der Weid, Pierre-Yves ;
Wang, Yuping ;
Alexander, J. Steven .
BIOMEDICINE & PHARMACOTHERAPY, 2018, 107 :1591-1600
[3]   PROSTAGLANDINS - EFFECTS ON BLOOD-PRESSURE, RENAL BLOOD-FLOW, SODIUM AND WATER-EXCRETION [J].
ANDERSON, RJ ;
BERL, T ;
MCDONALD, KM ;
SCHRIER, RW .
KIDNEY INTERNATIONAL, 1976, 10 (03) :205-215
[4]  
Bagni E, 1993, G ITAL CARDIOL, V23
[5]   WHAT CAUSES A BROKEN HEART-MOLECULAR INSIGHTS INTO HEART FAILURE [J].
Barry, Sean P. ;
Townsend, Paul A. .
INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY, VOL 284, 2010, 284 :113-179
[6]   ENZYMATIC FORMATION OF PROSTAGLANDIN E2 FROM ARACHIDONIC ACID PROSTAGLANDINS + RELATED FACTORS 32 [J].
BERGSTROM, S ;
DANIELSSON, H ;
SAMUELSSON, B .
BIOCHIMICA ET BIOPHYSICA ACTA, 1964, 90 (01) :207-&
[7]   Human prostaglandin EP3 receptor isoforms show different agonist-induced internalization patterns [J].
Bilson, HA ;
Mitchell, DL ;
Ashby, B .
FEBS LETTERS, 2004, 572 (1-3) :271-275
[8]   Cyclooxygenase involvement in thromboxane-dependent contraction in rat mesenteric resistance arteries [J].
Bolla, M ;
You, D ;
Loufrani, L ;
Levy, BI ;
Levy-Toledano, S ;
Habib, A ;
Henrion, D .
HYPERTENSION, 2004, 43 (06) :1264-1269
[9]  
BONDJERS G, 1991, CIRCULATION, V84, P2
[10]   Prostaglandin E receptors and the kidney [J].
Breyer, MD ;
Breyer, RM .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2000, 279 (01) :F12-F23